Final rule 2026-12900
Medical Devices; Clinical Chemistry and Toxicology Devices; Classification of the Prognostic Test for Development or Progression of Preeclampsia
The Food and Drug Administration (FDA) is classifying the prognostic test for development or progression of preeclampsia into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the prognostic test for development or progression of preeclampsia. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
Source-supplied record
Document details
- Document number
- 2026-12900
- Published
- Jun 26, 2026
- Effective
- Jun 26, 2026
- Comments close
- Not supplied
- Federal Register citation
- 91 FR 38496
Docket identifiers
- Docket No. FDA-2026-N-6731
CFR references
- Title 21, part 862